Therapeutic innovation in adult-onset Still's disease (and other rare inflammatory disorders): how to secure evidence-based medicine?
- PMID: 29860231
- DOI: 10.1136/annrheumdis-2018-213106
Therapeutic innovation in adult-onset Still's disease (and other rare inflammatory disorders): how to secure evidence-based medicine?
Keywords: adult onset still’s disease; inflammation; treatment.
Conflict of interest statement
Competing interests: PG is a medical expert for LFB (Laboratoire Français du Biofractionnement) and has received fees from Abbvie, Actelion, Boehringer Ingelheim France, Bouchara-Recordati, Novartis, Pfizer, and Roche in the last 5 years. ALeQ has received fees from Actelion, Bouchara-Recordati, GlaxoSmithKline, Intermune, LFB, Novartis, Pfizer, Roche, Shire and Zambon in the last 5 years. ATJM has received fees from Abbvie, Actelion, CSL Behring, Experf, Novartis and Shire in the last 5 years.
Comment on
-
Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still's disease.Ann Rheum Dis. 2018 Jun;77(6):840-847. doi: 10.1136/annrheumdis-2017-212608. Epub 2018 Feb 22. Ann Rheum Dis. 2018. PMID: 29472362 Free PMC article. Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources